Pathways to health outcomes after cancer diagnosis: A systematic review of cancer survivorship in Nigeria
Psycho-Oncology · 2023-07 · 32 (7) · 991-1000
DOI: 10.1002/pon.6167 ↗At a glance
Systematische Übersicht in Psycho-Oncology, published online on 2023-05-19. Written by Darlingtina K Esiaka and 5 co-authors. Institution: Department of Family Medicine and Community Health, Rutgers University, New Brunswick, New Jersey, USA. Major MEDLINE topics: Cancer Survivors, Physicians, Neoplasms. Cited 11 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH-Rutgers INSPIRE IRACDA Postdoctoral Program, Rhode Island Institutional Development Award (IDeA) Network of Biomedical Research Excellence.
Abstract (original language)
Objective
With advancements in medicine and technology, more people are surviving cancers. However, cancer mortality in Nigeria remains high. The yearly estimate is 72,000 cancer‐related deaths, making cancer one of the leading causes of death in Nigeria. The current study aimed to identify and synthesize factors that facilitate or hinder cancer survivorship in Nigeria and add to our understanding of the patterns of cancer survivorship in LMICs, such as Nigeria.
Method
Following preferred reporting items for systematic reviews and meta‐analyses guidelines, a systematic review was conducted across PubMed, Cochrane, and Scopus databases. We identified 31 peer‐reviewed studies that examined cancer treatment, management, care, and survivorship in Nigeria.
Results
Eight themes emerged from 31 peer‐reviewed studies that examined the factors that facilitate or hinder cancer survivorship among Nigerians. They include themes such as self‐care and management, treatment options, availability of pseudo‐doctors/pharmacists, and the desire to live. The themes were further grouped into three overarching themes: psychosocial, economic, and health care.
Conclusion
Cancer survivors in Nigeria face many unique experiences that impact their health outcomes and chances of survivorship. Therefore, understanding cancer survivorship in Nigeria must involve studies on diagnosis, treatment, remission, surveillance, after‐cancer care, and end‐of‐life. With enhanced support, cancer survivors will have improved health, thereby reducing the cancer mortality rate in Nigeria.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Family Medicine and Community Health, Rutgers University, New Brunswick, New Jersey, USA.
- Department of Health Sciences, Providence College, Providence, Rhode Island, USA.
- Department of Human Development and Family Sciences, University of Connecticut, Hartford, Connecticut, USA.
- Department of Theatre Arts, Federal University Lokoja, Lokoja, Kogi, Nigeria.
- Department of Social Work, University of Nigeria, Nsukka, Nigeria.
- Department of Neuroscience, Rutgers University, Newark, New Jersey, USA.
ORCID profiles: Darlingtina K Esiaka, Amarachi O Idu
Funding
- NIH-Rutgers INSPIRE IRACDA Postdoctoral Program
- Rhode Island Institutional Development Award (IDeA) Network of Biomedical Research Excellence
Cite
APA
Esiaka, D. K., Nwakasi, C., Nnamele, V. U., Idu, A. O., Egwuonwu, J., & Mahmoud, K. O. (2023). Pathways to health outcomes after cancer diagnosis: A systematic review of cancer survivorship in Nigeria. Psycho-Oncology, 32(7), 991-1000. https://doi.org/10.1002/pon.6167
Vancouver
Esiaka DK, Nwakasi C, Nnamele VU, Idu AO, Egwuonwu J, Mahmoud KO. Pathways to health outcomes after cancer diagnosis: A systematic review of cancer survivorship in Nigeria. Psycho-Oncology. 2023;32(7):991-1000. doi:10.1002/pon.6167
BibTeX
@article{Esiaka2023,
author = {Esiaka, Darlingtina K and Nwakasi, Candidus and Nnamele, Vincent U and Idu, Amarachi O and Egwuonwu, Joshua and Mahmoud, Kafayat O},
title = {Pathways to health outcomes after cancer diagnosis: A systematic review of cancer survivorship in Nigeria},
journal = {Psycho-Oncology},
year = {2023},
volume = {32},
number = {7},
pages = {991--1000},
doi = {10.1002/pon.6167}
}
EUVIMED